Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Acne (US)

Articles with lock require a subscription to GLG News | Request a free trial
March 17, 2008
Enbrel Significantly Improved Psoriasis in Children and Adolescents
Analysis of: New Study Reports Enbrel (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents | www.wyeth.com
Author: GLG Expert Contributor
The primary efficacy endpoint was PASI75 at week 12.  Patients were between 4 and 17 years old.  It was a 48-week study. There were 106 patients initially randomized to receive Enbrel and 105 patients randomized to receive placebo. At week 12, 57% (n=60) of pediatric patients treated...
March 14, 2008
Infliximab Works Well for Scalp, Trunk, and Extremities Affected by Psoriasis
Analysis of: Infliximab Shows Consistent Response Across All Body Regions in Psoriasis | www.medscape.com
Author: GLG Expert Contributor
PASI75 at week 10 was 70.6% in patients receiving infliximab 3 mg/kg and 79.3% in those receiving infliximab 5 mg/kg, compared with a PASI75 (only 2.7% of patients receiving placebo reached PASI75). PASI90 was achieved in 39.1% of those receiving 3 mg/kg and 52.0% in those receiving 5 mg/kg (only...
March 12, 2008
How will Apremilast (CC-10004) Affect the Treatment of Psoriasis?
Analysis of: Clinical Data Reported on Celgene Compound Apremilast (CC-10004) Evaluating Efficacy, Safety and Quality of Life Improvement for Psoriasis Patients | www.pipelinereview.com
Author: GLG Expert Contributor
The results demonstrated that 24.4% treated with 20 mg of oral apremilast every 12 hours reached PASI75 after 84 days (p=0.023), compared to a 10.3% reduction in the baseline score for those on placebo.  The treatment length was not mentioned in this article.
Sunil DhawanMarch 7, 2008
Renovo's Juvista product holds promose
Analysis of: Juvista Phase II Trial Results in Scar Revision and Breast Augmentation Surgery | www.renovo.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that this is an under served market. Current scar reduction products are only modestly effective, or not effective at all. An agent which has a "70% "reported reduction in scar appearance,is safe, and only has to be used a few times has a large market and will be successful....
March 7, 2008
Acambis’ Herpes Vaccine, dl5-29 HSV-2 Vaccine, Shows Promise for Genital Herpes
Analysis of: Acambis initiates pre-clinical testing with herpes vaccine from Harvard Medical School | www.pipelinereview.com
Author: GLG Expert Contributor
Acambis started pre-clinical trials with a herpes vaccine, dl5-29 HSV-2 vaccine.  Acambis holds an exclusive license under Harvard's patent rights to manufacture and sell the vaccine. There are no licensed HSV vaccines currently.
March 6, 2008
Acne Treatment for Adolescents
Analysis of: What Skin Care Routines and Treatments Are Effective for Adolescent Acne? | www.medscape.com
Author: GLG Expert Contributor
Topical retinoids, in order of weakest to strongest, include adapalene (Differin), tretinoin (either Avita or Retin-A), or tazarotene (Tazorac). Each time a new product or medication is begun, you must counsel the patient that any change in the regimen will take at least 6 weeks to show a differenc...
March 6, 2008
Juvista Improves the Appearance of Scars
Analysis of: Juvista Phase II Trial Results in Scar Revision and Breast Augmentation Surgery | www.renovo.com
Author: GLG Expert Contributor
Renovo Group announced two Phase 2 clinical trial results for its lead drug, Juvista (human recombinant TGFβ3) in scar revision (RN1001-1009) and breast augmentation (RN1001-1010) surgery.  In the scar revision trial, where Juvista was dosed twice, it met its primary endpoint with statistical...
Sunil DhawanMarch 6, 2008
Phosphagenics Topical Retinoic Acid Clinical Trial Initiated
Analysis of: Phosphagenics Initiates US Clinical Trials For Its Topical Retinoic Acid | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This new delivery system from Phosphagenics for enhancing absorption and reducing irritation will have moderate effect on the retinoid market. Retinoic Acid use has been in decline not so much because of irritation, but because of the introduction of more efficacious retinoids like Tazorac and Differin...
March 6, 2008
Galderma has Strengthened its Position as a Leader in Dermatology
Analysis of: CollaGenex Pharmaceuticals Agrees to $420M Galderma S.A. Takeover | www.fiercebiotech.com
Author: GLG Expert Contributor
Galderma has bought out CollaGenex for $420 million. In July 2006, CollaGenex launched Oracea®, the first FDA-approved systemic product for rosacea. CollaGenex is also developing Col-118, a novel product for the treatment of the erythema.
March 6, 2008
The Outlook of AS1409 for Melanoma
Analysis of: Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanoma | www.pipelinereview.com
Author: GLG Expert Contributor
Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces the entry of AS1409 into clinical trials. A phase I trial has started in patients with renal cancer and melanoma. The trial has two parts. In the first, successive cohorts of patients will receive increasing doses of AS1409....

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next31 to 40 of 191

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203